

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 June 2003 (19.06.2003)

PCT

(10) International Publication Number
WO 03/049687 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: PCT/US02/38898
- (22) International Filing Date: 5 December 2002 (05.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/338,320 6 December 2001 (06.12.2001) US
- (71) Applicant (*for all designated States except US*):
WELLER HEALTH, INC. [US/US]; 24881 Alicia
Parkway #E-341, Laguna Hills, CA 92653 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **EHRENPREIS**,
Seymour [US/US]; 4339 Birchwood Avenue, Skokie,
IL 60076 (US). **HOWARD, Lawrence** [US/US]; Weller
Health, INC, 24881 Alicia Parkway #E-341, Laguna Hills,
CA 92653 (US).
- (74) Agent: **CONNORS, John, J.**; Connors & Associates, Inc.,
1600 Dove Street #220, Newport Beach, CA 92660 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— *of inventorship (Rule 4.17(iv)) for US only*
- Published:**
— *without international search report and to be republished
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MEDICINAL COMPOSITIONS & THERAPEUTIC METHODS

(57) Abstract: The compositions of this invention comprise a mixture of (1) phenylalanine and a dietary food supplement, (2) leucine and a dietary food supplement, and (3) hydrocinnamic acid and a dietary food supplement. The compositions are used for medicinal purposes to alleviate a variety of maladies.

WO 03/049687 A2

BEST AVAILABLE COPY

MEDICINAL COMPOSITIONS & THERAPEUTIC METHODS

RELATED PATENT APPLICATIONS & INCORPORATION BY REFERENCE

This application is a PCT application based on U. S. provisional patent application Serial No. 60/338,320 entitled "Anti-Inflammation/Analgesic Compositions & Methods Of treating Arthritis And Other Painful Conditions," filed December 6, 2001. This related application is incorporated herein by reference and made a part of this application. If any conflict arises between the disclosure of the invention in this PCT application and that in the related provisional application, the disclosure in this PCT application shall govern. Moreover, Applicants incorporate herein by reference any and all U. S. patents, U. S. patent applications, and other documents cited or referred to in this application or cited or referred to in the U. S. patents and U. S. patent applications incorporated herein by reference.

DEFINITIONS

The words "comprising," "having," and "including," and other forms thereof, are intended to be equivalent in meaning and be open ended in that an item or items following any one of these words is not meant to be an exhaustive listing of such item or items, or meant to be limited to only the listed item or items.

The term "arthritis" means inflammation of the articular extremity of a bone resulting in erosion of the cartilage, loss of range of motion and pain.

BACKGROUND OF INVENTION

Phenylalanine is now shown by the inventors to be a medication for various maladies, including high blood pressure and pain relief, including treating arthritis. This amino acid includes D- phenylalanine (DPA) or D,L- phenylalanine (DLPA); the latter is a 50-50 mixture of the D and L forms of phenylalanine (DPA and LPA). Phenylalanine is considered to be a dietary supplement; DLPA is sold over-the-counter. DPA, but not LPA, is an inhibitor of enzymes that inactivate the naturally occurring peptides—the enkephalins and other endorphins; this compound is termed an enkephalinase inhibitor. Thus it is the DPA not LPA—the L form of phenylalanine—which is the active agent in providing relief in arthritis and other

1 painful conditions. As a result of this activity, levels of enkephalins in particular
2 have been shown to increase in the central nervous system in mice. As a result,
3 various painful conditions are relieved. DPA has been shown to have another
4 activity, namely, as an anti-inflammatory agent. These activities—analgesia plus
5 anti-inflammatory activity—suggest efficacy of DPA or DLPA in arthritis; data
6 indicating that this is indeed the case as presented below.

7 DPA also lowers above normal blood pressure. This is in contradistinction to
8 the conventional anti-hypertensive drugs that can significantly lower blood pressure
9 even if it is normal. The blood pressure-lowering effect of DPA is long-lasting in
10 both animals and humans. Thus, DPA may be administered as a once-a-day agent
11 to achieve a blood-pressure lowering effect. At the present time DPA appears to be
12 unique among inhibitors of endorphin degradation since it was demonstrated that
13 two other compounds with similar activities – thiorphan and actinonin – were
14 essentially devoid of anti-hypertensive activities.

15 In general, the causes of arthritis are not known, particularly osteoarthritis.
16 Rheumatoid arthritis appears to be an autoimmune disease. Arthritis in animals and
17 humans is attributed to the presence of excessive amounts of prostaglandins and
18 other products of the arachidonic acid cascade, and proteolytic enzymes elaborated
19 during the disease process, is treated by means of combinations of drugs and natural
20 products which serve to prevent the accumulation of pathophysiological factors.
21 Also, various painful conditions in animals and humans are treated by raising the
22 levels of endorphins in the central nervous system through these same means. A
23 primary agent in all such combinations of drugs and natural products is
24 phenylalanine, in doses sufficient to reverse, or prevent, the inflammation and pain
25 of arthritis, or many other painful conditions.

26 The sequence of events that occur in an arthritic joint is as follows:

27 If a pathophysiological event occurs, e.g. trauma, joint infection, autoimmune
28 response, the arachidonic acid cascade is activated resulting in the generation of
29 prostaglandins and leukotrienes; these substances promote inflammation and pain.
30 Cell membranes within the joint are damaged resulting in the release of proteolytic
31 enzymes, which can erode the cartilage. Also present within joint synovial fluid are
32 various endorphins (enkephalins, _ endorphin); these are analgesic peptides. Under
33 ordinary conditions, they would counteract the pain caused by the products of the
34 arachidonic acid cascade. However, if the conditions persist, or are particularly
35 severe, the condition becomes irreversible and full-blown arthritis ensues. The

1 reasons for this are as follows:

2 The amount of proteolytic enzymes released becomes sufficient to degrade
3 the joint cartilage causing its destruction. In addition, these enzymes degrade the
4 endorphins present. Finally, there is a build-up of the products of the arachidonic
5 acid cascade. The net result is continuing pain and inflammation, and loss of range
6 of motion, i.e., the arthritic condition.

7 There are several classes of drugs, which, to a certain extent, can alleviate the
8 painful condition as well as the inflammatory response. These include the
9 following: Various steroids, aspirin and other non-steroidal anti-inflammatory
10 drugs (NSAIDs) such as ibuprofen, indomethacin, naprosyn, sulindac, etc. These
11 drugs block the arachidonic acid cascade thereby providing relief from the
12 inflammation and pain caused by the prostaglandins and related compounds.

13 In addition, there are drugs which may slow down the progress of the
14 disease; these are called DMARDs (disease modifying anti-arthritic drugs) and
15 include methotrexate, cyclosporine, and various gold compounds. Unfortunately,
16 all of these drugs have a serious drawback in that they may cause serious, even fatal,
17 adverse reactions. In addition, these drugs are involved with many interactions with
18 other drugs, such interactions at times being very deleterious, and requiring difficult
19 adjustment of dosage for the interacting drugs.

20 More recently, several nutraceuticals have been introduced with some success
21 for arthritis treatment. Among these are glucosamine (GS), chondroitin sulfate
22 (CSA) and cetyl myristoleate. These naturally occurring compounds offer a new
23 approach to treatment, namely, to slow down, or perhaps even reverse, the
24 destruction of joint cartilage that is characteristic of arthritis. It should be noted that
25 none of these newer agents have analgesic or anti-inflammatory activity.

26 27 SUMMARY OF INVENTION 28

29 This invention, with its several desirable features, is summarized in the
30 CLAIMS that follow. After reading the following section entitled "DETAILED
31 DESCRIPTION OF SOME EMBODIMENTS OF THIS INVENTION," one will
32 understand how the features of this invention provide its benefits. The benefits of
33 this invention include, but are not limited to, treating the following maladies: high
34 blood pressure, osteoarthritis and rheumatoid arthritis, anxiety, depression,
35 psychological disorders such as, for example, ADHD and ADD, OCD, stress,

1 agorophobia, bulimia, anorexia, insomnia, lack of focus, craving including food,
2 drug and alcohol addictions, fibromyalgia, and pain including (1) preventing or
3 reversing the inflammation and chronic and acute pain of arthritis (2) reversing the
4 destruction of cartilage that is present in arthritis, and (3) headache, toothaches, low
5 back pain, musculoskeletal pain, pre-menstrual pain, pain due to sports injury,
6 carpal tunnel injury, broken bones, post operative surgery, and dental pain.

7 The compositions of this invention comprise:

8 (1) a mixture of phenylalanine and the dietary food supplement identified
9 below;

10 (2) a mixture of leucine and the dietary food supplement identified below;

11 (3) a mixture of hydrocinnamic acid and the dietary food supplement
12 identified below; and

13 (4) a mixture of and the dietary food supplement identified below and a blend
14 of any two of the phenylalanine, leucine, and hydrocinnamic acid of these
15 ingredients.

16 The phenylalanine, leucine, hydrocinnamic, or mixtures thereof, may be present in
17 an amount of from 5 to 95 weight percent and the dietary food supplement may be
18 present in an amount of from 5 to 95 weight percent. The phenylalanine may include
19 as the major component the D-phenylalanine, and the leucine may include as the
20 major component the D-leucine.

21 The dietary food supplements consist of glucosamine, chondroitin sulfate,
22 Cat's claw, Devil's claw, cetyl myristoleate, a mixture of a cetyl ester and cetyl
23 myristoleate, coenzyme Q-10, fructose 1-6 diphosphate, glutathione (reduced),
24 melatonin, Kava Kava extract, s-adenosylmethionine (SAmE), SAmE including as a
25 major component the (SS)-(+)-SAmE, bromelain, a mixture of white willow bark
26 powder and extract of salicin, either or both hydrolyzed and un-hydrolyzed Type II
27 Collagen, methyl-sulfonyl-methane, hyaluronic acid, pine bark extract, Citrulline, L-
28 tryptophine, Gingko Biloba, ginseng, St. John's Wort, creatine, Ribose, Ephedra,
29 Ephedrine, glutamine, L-carnitine, Androstene compounds, Citicoline, NADH, B-
30 Vitamins, Folic Acid, Biotin, Tyrosine, Vitamin C, Trimethylglycine, caffeine, protein
31 powders, and mixtures thereof..

32 The various individual combinations of the above ingredients are each unique
33 and some combinations are more suited to treating specific maladies than others as
34 discussed subsequently. Many of the more effective compositions include S-
35 adenosyl-L-methionine, and its salts, (either or both herein referred to as SAmE).

1 These SAME compounds are well known pharmacologically active compositions
2 that combat, for example, depression, arthritis, and liver diseases such as, for
3 example, cirrhosis. SAME occurs as two diastereoisomers: (RS)-(+)-SAME and (SS)-
4 (+)-SAME. The (SS)-(+)-SAM-e diastereoisomer is the pharmacologically active
5 diastereoisomer. In one embodiment of this invention the SAME includes as a major
6 component the diastereoisomer (SS)-(+)-SAME. For example, SAME products
7 containing (SS)-(+)-SAME at a concentration of at least 95 weight percent (%) of the
8 total diastereoisomers mixture are used. A suitable source of SAME, including the
9 SAME with the higher concentration of the (SS)-(+)-SAME diastereoisomer, Gnosis S.
10 r. 1. of Milan, Italy.

11 The compositions of this invention may include a therapeutic amount of an
12 anti-depressant medicinal substance such as, for example, fluoxetine, anti-
13 depressants in the SSRI class, or tricyclic anti-depressants. These anti-depressant
14 medicinal substances are typically prescription drugs that have adverse side effects.
15 Reduce dosages of these drugs are employed in the compositions of this invention.

16 The compositions of this invention are easily administered by the oral route.
17 For example, oral administration via tablets (plain or enteric coated and/or time
18 released), caplets (plain or enteric coated and/or time released), liquids, drinks
19 (ready made or drinks by adding liquid), oral sprays and gels and soft gels (plain or
20 enteric coated and/or time released). In addition to oral administration, the
21 compositions of this invention may be administered by IV's, suppositories, creams,
22 nasal sprays, inhalants, muscle/skeletal injections, added to foods, energy bars, etc.,
23 and patches. These compositions may be given in dosages that are safe and provide
24 therapeutic efficacy at such dosages. For example, even trace amounts may be
25 beneficial such as, for example, as low as 1 microgram. Typically, the dosage of the
26 composition is from 1 to 400 grams per day, divided, preferably equally, into from 2
27 to 4 applications per day. In many instances, a dosage of 2-4 grams once a day is
28 adequate.

30 DETAILED DESCRIPTION OF SOME EMBODIMENTS OF THIS INVENTION

31

32 In one embodiment particularly suited for treating high blood pressure, the
33 phenylalanine or leucine or hydrocinnamic acid (or mixtures of two or more) is
34 mixed with Co-Q-10, or Citrulline, or L-Glutamine, or Glutathione, or L-
35 Tryptophane, or mixtures thereof. In one embodiment particularly suited for

1 treating high blood pressure, phenylalanine or leucine or hydrocinnamic acid is
2 mixed with a therapeutic amount of an anti-hypertensive drug especially
3 appropriate for this use. These compositions are especially useful when they include
4 a dietary food supplement such as Co-Q-10. Examples of such anti-hypertensive
5 drugs include blood vessel dilators such as diazoxide and diuretics such as a
6 thiazide diuretic such as hydrochlorothiazide, a loop diuretic such as furosemide, a
7 potassium-sparing diuretic such as triamterene, an adrenergic-beta-blocking agent a
8 beta blocker such as propranolol, an angiotensin converting enzyme inhibitor such
9 as lisinopril, an angiotensin II receptor, antagonist such as losartan, an alpha-blocker
10 such as prazosin, a calcium channel blocker such as verapamil, a T-type calcium
11 antagonist including for example, adrenergic agonist such as clonidine, an inhibitor
12 of norepinephrine sythesis selected from the group consisting of methyl-p-tyrosine,
13 diethyldithiocarbonate, inhibitors of dopamine_-hydroxylase, a source of
14 magnesium, Bestatin, Thiorphan.

15 In one embodiment particularly suited for reducing pain accompanying
16 athletic exercise, improving endurance, strength, and performance, the
17 phenylalanine or leucine or hydrocinnamic acid is mixed with Caffeine, Creatine,
18 Ribose, Phosphates, Branch Chain Amino's, FDP, etc., strength and body building
19 protein powders, Ephedra or Ephedrine, e. g., those found in herbs, Creatine,
20 Glutamine, L-Carnitine, Androstene compounds or mixtures thereof.

21 In one embodiment particularly suited for improved brain functions, the
22 phenylalanine or leucine or hydrocinnamic acid is mixed with Gingko Biloba,
23 Ginseng, St. John's Wort, Huperzine, Phosphatidyl Choline, Phosphatidyl Serine,
24 Wild Jujube Seed. Additionally, N-Acetyl-Glucosamine, Green Tea, Ginseng,
25 Vitamin B-1,B-2, B-3, B-5, B-6, B-12, Folic Acid, Biotin, L-Tyrosine, Acetyl-L-
26 Cysteine, Magnesium, Vitamin C may be added to this mixture.

27 In one embodiment particularly suited for improved mental health, with
28 SAME, Glutathione, Co-Q-10, Citicoline, NADH, B-Vitamins. Folic acid, Biotin,
29 Tyrosine, GABA, L-Glutamine, Vitamin C, and Trimethylglycine.

30 In one embodiment for treating arthritis, a therapeutic amount of the primary
31 agent phenylalanine is blended with a therapeutic amount of one or more of the
32 dietary food supplements set forth in Table 7. In a second embodiment of this
33 invention, one or more of the following: aspirin, acetaminophen, or a non-selective,
34 non-steroidal, anti-inflammatory drug (NSAID), as well as COX 2 inhibitors
35 (NSAID), is added to the blend of phenylalanine and dietary food supplement of the

1 first embodiment. One especially beneficiary composition is a blend of
2 phenylalanine, acetaminophen, and therapeutic amount of glutathione. One or more
3 of the NSAIDs listed in Table 6 may be used. Preferably D-phenylalanine is used in
4 both embodiments. In all these embodiments, the amount of D-phenylalanine
5 administered is between approximately 10 and approximately 3000mg/day, and the
6 amount of D,L-phenylalanine administered is between approximately 20 and
7 approximately 6000mg/day. Administration may be in the form of a tablet or a
8 capsule.

9 Each of the components of the proposed combinations provides some
10 advantages over individual usage. DPA/DLPA provides relief of pain, as do the
11 NSAIDs. The combination of NSAIDs with D-phenylalanine or D,L-phenylalanine
12 has been shown to greatly enhance the analgesia provided by the NSAIDs alone.
13 Thus, the combination provides pain relief for those who fail to respond, or respond
14 inadequately, to D-phenylalanine or D,L-phenylalanine alone or NSAIDs alone.
15 DPA/DLPA combined with the NSAIDs have potent anti-inflammatory activities.
16 DPA/DLPA is extremely safe as shown both in animal and human studies.
17 Glucosamine and chondroitin sulfate can promote regeneration of cartilage, which
18 may be destroyed in arthritis. Thus, the combinations discussed above provide the
19 following advantages over using them individually:

- 20 1. Greater efficacy for relief of pain.
- 21 2. Reduced drug toxicity, in particular by reducing the dosage of
22 acetaminophen, aspirin and other NSAIDs.
- 23 3. Reduced incidence of drug-drug interactions due to the reduction in dosage
24 of aspirin or other NSAIDs.
- 25 4. Reversal of inflammation.
- 26 5. Reversal of cartilage destruction.
- 27 6. Rebuilding of cartilage destroyed by the arthritic processes.
- 28 7. Prevention of recurrence of the disease.

29 One aspect of the present invention is to use phenylalanine, leucine or
30 hydrocinnamic acid, or combinations of these ingredients, to inhibit the enzymes
31 that inactivate certain endorphins, thereby permitting these endorphins to
32 accumulate in the central nervous system and the synovial fluid of joints. In so
33 doing, these endorphins relieve the unwanted symptoms. For example, when
34 treating arthritis, the pain and inflammation are reduced by providing analgesia for
35 painful conditions. The compositions of this invention may include NSAIDs known

1 to be effective in treating pain and inflammation, namely, aspirin, ibuprofen, etc.,
2 permitting the use of lower doses of each component to achieve the desired effect.
3 As a result, adverse effects as well as drug-drug interactions are reduced.

4 Another aspect of the present invention is to use phenylalanine, leucine or
5 hydrocinnamic acid, or combinations of these ingredients, at a dosage sufficient to
6 relieve pain and inflammation of arthritis and the pain that accompanies such
7 conditions as headache, low back pain, musculoskeletal pain, dental pain and pre-
8 menstrual pain.

9 All of the compounds and combinations described above can be offered as
10 pharmaceutically accepted formulations using methods known to those of ordinary
11 skill in the art. Some of these formulations may only be administered by the oral
12 route, whether solely or in combination. The dosage of phenylalanine, leucine or
13 hydrocinnamic acid, or combinations of these ingredients, or in combination with
14 any of the other compounds, will depend on the severity of the arthritic, or other
15 painful condition, as well as any existing or potential co-morbidity. It should be
16 noted that the present invention has application for both human and veterinary use.
17 Suggested oral dosages for humans are shown in Table 5. Formulations for human
18 use will be in the form of tablets or capsules, normal and sustained release.

20 BRIEF DESCRIPTION OF THE TABLES

22 **Table 1:** Anti-inflammatory activity of DPA using the rat paw carrageenan method.

24 **Table 2:** Anti-inflammatory activity of DPA using the mouse writhing test.

26 **Table 3:** Analgesic activity of DPA using the mouse hot plate method. Combination
27 of DPA with indomethacin and sulindac, two NSAIDs.

29 **Table 4:** Efficacy of DPA in arthritis and a variety of other musculoskeletal diseases:
30 human studies.

32 **Table 5:** Suggested dosage schedule for treating arthritis in humans using DPA or
33 DLPA alone or in combination with various other compounds.

35 **Table 6:** List of NSAIDs, including COX 2 Inhibitors

Table 7: List of dietary food supplements combined with DPA

**DETAILED DESCRIPTION OF THE METHODS CITED ABOVE
AND RESULTS OBTAINED**

1. Anti-inflammatory activity of DPA using the rat paw carrageenan method.

This is a generally recognized method for evaluating anti-inflammatory drugs of the aspirin/NSAID type or those that counteract the action of the prostalands. Such drugs are useful for treating conditions such as arthritis in animals and humans. In this method, the rat paw of the rat is injected with carrageenan, which causes swelling of the paw due to accumulation of fluid. A drug that prevents this swelling would be expected to have anti-inflammatory and hence anti-arthritis activity in humans. In this study, DPA was administered by various routes and times into groups of rats (6 male albino rats per group—weight approximately 250grams) before carrageenan and the degree of swelling was measured by the extent of displacement of water when the paw was immersed into a calibrated cylinder. A placebo consisting of saline solution was similarly administered. Results are shown in Table 1.

TABLE 1: Anti-inflammatory activity of DPA using the rat paw carrageenan method

A. Subcutaneous injection

		% inhibition of swelling
120 minutes before carrageenan	Placebo	0
	DPA 8mg/kg	15
	125mg/kg	37
	500mg/kg	35
6 hours before carrageenan	Placebo	0
	DPA 62.5	35
	250	36
	500	75

B. Oral administration

150 minutes before carrageenan		% inhibition of swelling
	Placebo	0
	DPA 125mg/kg	7
	250mg/kg	10
	500mg/kg	24
	1000mg/kg	62
	1500mg/kg	79

2. Anti-inflammatory activity of DPA using the mouse phenylbenzylquinone (PBQ) writhing test.

This is a generally recognized method for evaluating anti-inflammatory drugs of the aspirin/NSAID type; those drugs which counteract the action of the prostaglandins. Such drugs are useful for treating conditions such as arthritis in animals and humans.

In this method a solution of PBQ is injected intra-peritoneally into groups of 6 mice (male, albino, 22-25 grams). Within a few minutes, the mice began to writhe. DPA was injected subcutaneously or given by mouth at different times prior to PBQ. The number of writhes were counted over a period of 20 minutes. The effects of DPA were compared to that of similarly administered saline control. Results are shown in Table 2. A drug that blocks writhing would be expected to have anti-inflammatory and hence anti-arthritic activity in humans.

TABLE 2: *Anti-inflammatory activity of DPA using the mouse writhing test*

A. Subcutaneous injection, 6 hours before PBQ

	Number of writhes	% inhibition of writhing
Saline	110	

DPA 500mg/kg	28	75
Saline	166	—
DPA, 250mg/kg	106	36
62.5mg/kg	108	35

B. Oral administration of DPA, 2.5 hours before PBQ

	Number of writhes	% inhibition of writhing
Saline	148	—
DPA, 250mg/kg	133	10
500mg/kg	110	24
1000mg/kg	56	62

C. Intraperitoneal injection of DPA, 2 hours before PBQ

	Number of writhes	% inhibition of writhing
Saline	125	—
DPA, 250mg/kg	34	73
500mg/kg	13	90

3. Analgesic activity of DPA using the mouse hot plate test.

The mouse hot plate is a generally recognized method for evaluating analgesic drugs that act on the endorphin system, e.g., morphine-like drugs and drugs that increase endorphin levels, e.g., DPA. Such drugs are useful for treating many kinds of painful conditions including arthritis, headache, low back pain, musculoskeletal pain, pre-menstrual pain, and dental pain.

In this method, groups of mice (6 albino mice per group, weighing between 22 and 25 grams) are individually placed on a hot plate at 55°C and a beaker is

placed over the mouse. The time for the mouse to jump in an attempt to escape the painful condition is recorded. An analgesic substance is one which increases the threshold to pain thereby permitting the mouse to remain on the hot plate for longer times. The effect of the drug is compared to that of a saline control. DPA at different doses was injected intraperitoneally into the mice 2 hours before they were placed on the hot plate, and jumping time determined over the next 1-2 hours. The effect of DPA was compared with that of an injection of saline.

For studies involving combinations of drugs, the combination was injected at the same time. In the studies shown below, the second drug consisted of indomethacin, diclofenac or acetaminophen. Each of these drugs is used for treating arthritis as well as many other painful conditions.

Table 3: Analgesic activity of DPA, DPA plus indomethacin, DPA plus diclofenac and DPA plus acetaminophen using the mouse hot plate method

	Increase in threshold to jumping compared to control
DPA, 250mg/kg	3-fold
Indomethacin, 20mg/kg	0
DPA, 250mg/kg PLUS Indomethacin, 20mg/kg	11-fold
Diclofenac, 20mg/kg	0
DPA, 250mg/kg PLUS diclofenac, 20mg/kg	12-fold

The importance of this experiment is the demonstration that the combination of DPA plus a NSAIDS such as indomethacin or diclofenac provides a greatly enhanced degree of analgesia. The analgesia produced is far greater than the sum of the individual drugs.

A similar result was obtained when DPA was combined with acetaminophen (Tylenol).

4. Efficacy of DPA in arthritis and a variety of other musculoskeletal diseases; human studies.

Forty-three patients were studied in an open-label, cross-over procedure. Of these, 32 had arthritis. All of the patients had previously been given many treatments without success in relieving their pain. Pre-DPA administration treatments used included such potent drugs as Percodan, Darvocet, Valium and aspirin as well as acupuncture. Prior to giving DPA 800mg/day by mouth, all treatments were stopped. Patients were given a card in which they scored their degree of pain on a scale of 1-4: 1 indicated no relief, 2 approximately 25% relief, 3 approximately 50% relief, and 4 complete relief. Results are shown in Table 4.

TABLE 4: Efficacy of DPA in humans with arthritis and other skeletal diseases

Complete relief of pain	Excellent relief of pain	Moderate relief of pain	No relief of pain
2	7	19	15*

*Most of these patients took DPA for only 1-2 weeks. They discontinued the DPA because of lack of success. For very severe conditions, DPA should be taken for longer periods of time and at even higher doses.

What these human results show is that DPA alone at the moderate dose of 800mg/day could successfully decrease one of the prominent signs of these diseases, namely pain.

Pain is perhaps the most debilitating aspect of arthritis. In this invention, we propose to use DPA or DLPA along with other drugs or natural substances in order to enhance the analgesic efficacy of DPA in arthritis. Table 5 presents some suggested dosages for using DPA, or DLPA alone, or in combination with the various compounds discussed previously for treating arthritis and a variety of painful conditions in humans.

TABLE 5: Suggested dosage schedule for treating arthritis and other painful conditions in humans using DPA, DLPA alone or in combination with various other compounds

Dose of DPA	Dose of DLPA	Dose of second component
10-3000mg/day	—	—
—	20-6000mg/day	—

10-3000mg/day	--	Glucosamine:
	20-6000mg/day	1000-1500mg/day
		Glucosamine:
		1000-1500mg/day
10-3000mg/day	--	Chondroitin sulfate: 100-
	20-6000mg/day	1000mg/day
		Chondroitin sulfate: 100-
		1000mg/day
10-3000mg/day	--	Aspirin: 85-3000mg/day
	20-6000mg/day	Aspirin: 85-3000mg/day
10-3000mg/day	--	Ibuprofen:
	20-6000mg/day	200-2000mg/day
		Ibuprofen:
		200-2000mg/day
10-3000mg/day	--	Indomethacin:
	20-6000mg/day	10-400mg/day
		Indomethacin:
		10-400mg/day

1 Similar combinations of DPA or DLPA with all other NSAIDs are herein proposed
 2 including the new COX 2 inhibitors. (See Table 6)

3
 4 **Table 6:** List of NSAIDs, including COX 2 Inhibitors

Name	Approximate doses mg/day
diclofenac	25-300
Etadolac	100-1500
fenoprofen	300-4000
fluriprofen	100-600
ibuprofen	200-6000
indomethacin	10-400
ketoprofen	50-400
ketorolac	10-120
meclofenamate	100-800

nabumetone	250-4000
naproxen	100-3000
oxaprozin	600-3000
piroxicam	5-40
sulindac	50-1000
tolmetin	400-4000
rofecoxib	10-150
celecoxib	100-400

TABLE 7: List of Nutraceuticals to be combined with DPA/DLPA (all Weight Percentages About 5% - about 90%)

Name	Approximate doses
Glucosamine	500-2000mg/day
Chondroitin Sulfate	400-1000mg/day
Cats Claw (Uncaria tomentosa)	20-100mg/day
Devils Claw (Harpagophytum procumbens)	400-600mg/day
Cetyl Myristoleate (CMO)	100-800mg/day
Cetyl Esters with CMO	100-800mg/day
Coenzyme Q-10	60-200mg/day
Fructose 1,6 diphosphate	2-10g/day
Glutathione	100-700mg/day
Melatonin	3-10mg/day
Kava Kava Extract, 30%	200-800mg/day
SAM-e	400-1200mg/day
Bromelain	60-160mg/day
White Willow Bark powder and extract 0.05-99% Salicin	100-500mg/day
Type II Collagen	100-2400mg/day
Methyl-sulfonyl-methane (MSM)	500-2500mg/day

SCOPE OF THE INVENTION

The above presents a description of the best mode contemplated of carrying out the present invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains to make and use this invention. This invention is, however, susceptible to modifications and alternate constructions from that discussed above which are fully equivalent. Consequently, it is not the intention to limit this invention to the particular embodiments disclosed. On the contrary, the intention is

1. to cover all modifications and alternate constructions coming within the spirit and
2. scope of the invention as generally expressed by the following claims, which
3. particularly point out and distinctly claim the subject matter of the invention:

CLAIMS

1. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of glucosamine.
2. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of chondroitin sulfate.
3. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of Cat's claw.
4. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of Devil's claw.
5. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of cetyl myristoleate.
6. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of a mixture of a cetyl ester and cetyl myristoleate.
7. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of coenzyme Q-10.
8. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of fructose 1-6 diphosphate.
9. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of glutathione.
10. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of melatonin.
11. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of Kava Kava extract.
12. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of s-adenosylmethionine (SAM-e).
13. The composition according to Claim 12 where the SAME includes as a major component the (SS)-(+)-SAME.
14. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of bromelain.
15. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of a mixture of white willow bark powder and extract of salicin.
16. A composition comprising a therapeutic amount of phenylalanine and a therapeutic amount of either or both hydrolyzed and un-hydrolyzed Type II Collagen.

- 1 17. A composition comprising a therapeutic amount of phenylalanine and a
2 therapeutic amount of methyl-sulfonyl-methane.
- 3 18. A composition comprising a therapeutic amount of phenylalanine and a
4 therapeutic amount of hyaluronic acid.
- 5 19. A composition comprising a therapeutic amount of phenylalanine and a
6 therapeutic amount of pine bark extract.
- 7 20. A composition comprising a therapeutic amount of phenylalanine and a
8 therapeutic amount of Citrulline.
- 9 21. A composition comprising a therapeutic amount of phenylalanine and a
10 therapeutic amount of L-tryptophine.
- 11 22. A composition comprising a therapeutic amount of phenylalanine and a
12 therapeutic amount of Gingko Biloba.
- 13 23. A composition comprising a therapeutic amount of phenylalanine and a
14 therapeutic amount of ginseng.
- 15 24. A composition comprising a therapeutic amount of phenylalanine and a
16 therapeutic amount of St. John's Wort.
- 17 25. A composition comprising a therapeutic amount of phenylalanine and a
18 therapeutic amount of creatine.
- 19 26. A composition comprising a therapeutic amount of phenylalanine and a
20 therapeutic amount of Ribose.
- 21 27. A composition comprising a therapeutic amount of phenylalanine and a
22 therapeutic amount of Ephedra.
- 23 28. A composition comprising a therapeutic amount of phenylalanine and a
24 therapeutic amount of Ephedrine.
- 25 29. A composition comprising a therapeutic amount of phenylalanine and a
26 therapeutic amount of glutamine.
- 27 30. A composition comprising a therapeutic amount of phenylalanine and a
28 therapeutic amount of L-carnitine.
- 29 31. A composition comprising a therapeutic amount of phenylalanine and a
30 therapeutic amount of Androstene compounds.
- 31 32. A composition comprising a therapeutic amount of phenylalanine and a
32 therapeutic amount of Citicoline.
- 33 33. A composition comprising a therapeutic amount of phenylalanine and a
34 therapeutic amount of NADH.
- 35 34. A composition comprising a therapeutic amount of phenylalanine and a

- 1 therapeutic amount of B-Vitamins.
- 2 35. A composition comprising a therapeutic amount of phenylalanine and a
- 3 therapeutic amount of Folic Acid.
- 4 36. A composition comprising a therapeutic amount of phenylalanine and a
- 5 therapeutic amount of Biotin.
- 6 37. A composition comprising a therapeutic amount of phenylalanine and a
- 7 therapeutic amount of Tyrosine.
- 8 38. A composition comprising a therapeutic amount of phenylalanine and a
- 9 therapeutic amount of Vitamin C.
- 10 39. A composition comprising a therapeutic amount of phenylalanine and a
- 11 therapeutic amount of Trimethylglycine.
- 12 40. A composition comprising a therapeutic amount of phenylalanine and a
- 13 therapeutic amount of caffeine.
- 14 41. A composition comprising phenylalanine and protein powders.
- 15 42. The composition of Claims 1 through 41 additionally including a therapeutic
- 16 amount of aspirin.
- 17 43. The composition of Claims 1 through 41 additionally including a therapeutic
- 18 amount of acetaminophen.
- 19 44. The composition of Claims 1 through 41 additionally including a therapeutic
- 20 amount of a NSAIDS.
- 21 45. The composition of Claims 1 through 41 additionally including a therapeutic
- 22 amount of Motrin.
- 23 46. The composition according to Claims 1 through 41 where the phenylalanine
- 24 includes as a major component the D-phenylalanine.
- 25 47. A composition comprising a therapeutic amount of leucine and a therapeutic
- 26 amount of glucosamine.
- 27 48. A composition comprising a therapeutic amount of leucine and a therapeutic
- 28 amount of chondroitin sulfate.
- 29 49. A composition comprising a therapeutic amount of leucine and a therapeutic
- 30 amount of Cat's claw.
- 31 50. A composition comprising a therapeutic amount of leucine and a therapeutic
- 32 amount of Devil's claw.
- 33 51. A composition comprising a therapeutic amount of leucine and a therapeutic
- 34 amount of cetyl myristoleate.
- 35 52. A composition comprising a therapeutic amount of leucine and a therapeutic

- 1 amount of a mixture of a cetyl ester and cetyl myristoleate.
- 2 53. A composition comprising a therapeutic amount of leucine and a therapeutic
- 3 amount of coenzyme Q-10.
- 4 54. A composition comprising a therapeutic amount of leucine and a therapeutic
- 5 amount of fructose 1-6 diphosphate.
- 6 55. A composition comprising a therapeutic amount of leucine and a therapeutic
- 7 amount of glutathione.
- 8 56. A composition comprising a therapeutic amount of leucine and a therapeutic
- 9 amount of melatonin.
- 10 57. A composition comprising a therapeutic amount of leucine and a therapeutic
- 11 amount of Kava Kava extract.
- 12 58. A composition comprising a therapeutic amount of leucine and a therapeutic
- 13 amount of s-adenosylmethionine (SAM-e).
- 14 59. The composition according to Claim 58 where the SAME includes as a major
- 15 component the (SS)-(+)-SAME.
- 16 60. A composition comprising a therapeutic amount of leucine and a therapeutic
- 17 amount of bromelain.
- 18 61. A composition comprising a therapeutic amount of leucine and a therapeutic
- 19 amount of a mixture of white willow bark powder and extract of salicin.
- 20 62. A composition comprising a therapeutic amount of leucine and a therapeutic
- 21 amount of either or both hydrolyzed and un-hydrolyzed Type II Collagen.
- 22 63. A composition comprising a therapeutic amount of leucine and a therapeutic
- 23 amount of methyl-sulfonyl-methane.
- 24 64. A composition comprising a therapeutic amount of leucine and a therapeutic
- 25 amount of hyaluronic acid.
- 26 65. A composition comprising a therapeutic amount of leucine and a therapeutic
- 27 amount of pine bark extract.
- 28 66. A composition comprising a therapeutic amount of leucine and a therapeutic
- 29 amount of Citrulline.
- 30 67. A composition comprising a therapeutic amount of leucine and a therapeutic
- 31 amount of L-tryptophine.
- 32 68. A composition comprising a therapeutic amount of leucine and a therapeutic
- 33 amount of Gingko Biloba.
- 34 69. A composition comprising a therapeutic amount of leucine and a therapeutic
- 35 amount of ginseng.

- 1 70. A composition comprising a therapeutic amount of leucine and a therapeutic
2 amount of St. John's Wort.
- 3 71. A composition comprising a therapeutic amount of leucine and a therapeutic
4 amount of creatine.
- 5 72. A composition comprising a therapeutic amount of leucine and a therapeutic
6 amount of Ribose.
- 7 73. A composition comprising a therapeutic amount of leucine and a therapeutic
8 amount of Ephedra.
- 9 74. A composition comprising a therapeutic amount of leucine and a therapeutic
10 amount of Ephedrine.
- 11 75. A composition comprising a therapeutic amount of leucine and a therapeutic
12 amount of glutamine.
- 13 76. A composition comprising a therapeutic amount of leucine and a therapeutic
14 amount of L-carnitine.
- 15 77. A composition comprising a therapeutic amount of leucine and a therapeutic
16 amount of Androstene compounds.
- 17 78. A composition comprising a therapeutic amount of leucine and a therapeutic
18 amount of Citicoline.
- 19 79. A composition comprising a therapeutic amount of leucine and a therapeutic
20 amount of NADH.
- 21 80. A composition comprising a therapeutic amount of leucine and a therapeutic
22 amount of B-Vitamins.
- 23 81. A composition comprising a therapeutic amount of leucine and a therapeutic
24 amount of Folic Acid.
- 25 82. A composition comprising a therapeutic amount of leucine and a therapeutic
26 amount of Biotin.
- 27 83. A composition comprising a therapeutic amount of leucine and a therapeutic
28 amount of Tyrosine.
- 29 84. A composition comprising a therapeutic amount of leucine and a therapeutic
30 amount of Vitamin C.
- 31 85. A composition comprising a therapeutic amount of leucine and a therapeutic
32 amount of Trimethylglycine.
- 33 86. A composition comprising a therapeutic amount of leucine and a therapeutic
34 amount of caffeine.
- 35 87. A composition comprising leucine and protein powders.

- 1 88. The composition of Claims 47 through 87 additionally including a therapeutic
2 amount of aspirin.
- 3 89. The composition of Claims 47 through 87 additionally including a therapeutic
4 amount of acetaminophen.
- 5 90. The composition of Claims 47 through 87 additionally including a therapeutic
6 amount of a NSAIDS.
- 7 91. The composition of Claims 47 through 87 additionally including a therapeutic
8 amount of Motrin.
- 9 92. The composition according to Claims 47 through 91 where the leucine
10 includes as a major component the D - leucine.
- 11 93. A composition comprising a therapeutic amount of hydrocinnamic acid and a
12 therapeutic amount of glucosamine.
- 13 94. A composition comprising a therapeutic amount of hydrocinnamic acid and
14 a therapeutic amount of chondroitin sulfate.
- 15 95. A composition comprising a therapeutic amount of hydrocinnamic acid and
16 a therapeutic amount of Cat's claw.
- 17 96. A composition comprising a therapeutic amount of hydrocinnamic acid and
18 a therapeutic amount of Devil's claw.
- 19 97. A composition comprising a therapeutic amount of hydrocinnamic acid and
20 a therapeutic amount of cetyl myristoleate.
- 21 98. A composition comprising a therapeutic amount of hydrocinnamic acid and
22 a therapeutic amount of a mixture of a cetyl ester and cetyl myristoleate.
- 23 99. A composition comprising a therapeutic amount of hydrocinnamic acid and
24 a therapeutic amount of coenzyme Q-10.
- 25 100. A composition comprising a therapeutic amount of hydrocinnamic
26 acid and a therapeutic amount of fructose 1-6 diphosphate.
- 27 101. A composition comprising a therapeutic amount of hydrocinnamic
28 acid and a therapeutic amount of glutathione.
- 29 102. A composition comprising a therapeutic amount of hydrocinnamic
30 acid and a therapeutic amount of melatonin.
- 31 103. A composition comprising a therapeutic amount of hydrocinnamic
32 acid and a therapeutic amount of Kava Kava extract.
- 33 104. A composition comprising a therapeutic amount of hydrocinnamic
34 acid and a therapeutic amount of s-adenosylmethionine (SAM-e).
- 35 105. The composition according to Claim 104 where the SAME includes as a

major component the (SS)-(+)-SAME.

106. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of bromelain.

107. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of a mixture of white willow bark powder and extract of salicin.

108. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of either or both hydrolyzed and unhydrolyzed Type II Collagen.

109. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of methyl-sulfonyl-methane.

110. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of hyaluronic acid.

111. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of pine bark extract.

112. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Citrulline.

113. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of L-tryptophine.

114. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Gingko Biloba.

115. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of ginseng.

116. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of St. John's Wort.

117. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of creatine.

118. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Ribose.

119. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Ephedra.

120. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Ephedrine.

121. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of glutamine.

122. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of L-carnitine.
123. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Androstene compounds.
124. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Citicoline.
125. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of NADH.
126. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of B-Vitamins.
127. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Folic Acid.
128. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Biotin.
129. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Tyrosine.
130. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Vitamin C.
131. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of Trimethylglycine.
132. A composition comprising a therapeutic amount of hydrocinnamic acid and a therapeutic amount of caffeine.
133. A composition comprising hydrocinnamic acid and protein powders.
134. The composition of Claims 93 through 133 additionally including a therapeutic amount of aspirin.
135. The composition of Claims 93 through 133 additionally including a therapeutic amount of acetaminophen.
136. The composition of Claims 93 through 133 additionally including a therapeutic amount of a NSAIDS.
137. The composition of Claims 93 through 133 additionally including a therapeutic amount of Motrin.
138. The composition of Claims 1 through 137 additionally including a therapeutic amount of an anti-depressant medicinal substance.
139. The composition of Claim 138 where the anti-depressant medicinal substance is fluoxetine, anti-depressants in the SSRI class, or tricyclic anti-

depressants.

140. A method of treating high blood pressure, pain, depression, arthritis including associated pain, inflammation and erosion of cartilage, or anxiety comprising administering a therapeutic effective amount of one or more of the compositions of Claims of 1 through 139.

141. The method of increasing body strength and endurance for improved performance in athlete activities comprising orally ingesting substantially consistently a compound selected from the group consisting of phenylalanine, leucine, hydrocinnamic acid, and mixtures thereof.

142. The method according to Claim 141 where said compound is ingested substantially daily at least 1 week prior to an athlete activity in an amount from 50 milligrams to 400 grams.

143. The method according to Claim 142 where said compound includes a dietary food supplement.

144. The method according to Claim 143 where said dietary food supplement is selected from the group consisting of glucosamine, chondroitin sulfate, Cat's claw, Devil's claw, cetyl myristoleate, a mixture of a cetyl ester and cetyl myristoleate, coenzyme Q-10, fructose 1-6 diphosphate, glutathione, melatonin, Kava Kava extract, s-adenosylmethionine (SAM-e), SAMe including as a major component the (SS)-(+)-SAMe, bromelain, a mixture of white willow bark powder and extract of salicin, either or both hydrolyzed and un-hydrolyzed Type II Collagen, methyl-sulfonyl-methane, hyaluronic acid, pine bark extract, Citrulline, L-tryptophine, Ginkgo Biloba, ginseng, St. John's Wort, creatine, Ribose, Ephedra, Ephedrine, glutamine, L-carnitine, Androstene compounds, Citicoline, NADH, B-Vitamins, Folic Acid, Biotin, Tyrosine, Vitamin C, Trimethylglycine, caffeine, protein powders, and mixtures thereof.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.